Connect with us

Health

Health news in brief

Clinical trial discrimination investigation sought & more

Published

on

Clinical trial discrimination investigation sought

WASHINGTON — Five U.S. senators are asking Health & Human Services Secretary Kathleen Sebelius to investigate reports that gays and lesbians are being excluded from medical clinical trials.

A recent study conducted by the New England Journal of Medicine found that gay and lesbian patients were barred from participating in clinical trials, many dealing with sexual function. The letter from Sens. Sherrod Brown (D-Ohio), Kirstin Gillibrand (D-N.Y.), John Kerry (D-Mass.), Robert Menendez (D-N.J.) and Jeff Merkley (D-Ore.) asks Sebelius to determine if there is any proven medical rationale behind the practice.

“The New England Journal of Medicine is the gold standard for the medical community, and their study set off alarm bells,” Kerry said. “This is more than an equality issue. It raises huge questions about the quality of medical information from flawed trials.”

Merkley noted that for years, women were excluded from participating in clinical trials of medical treatments.

“This meant that American women were not represented in medical research of diseases and treatments that were prevalent among both men and women,” he said. “Today, this trend continues with individuals being excluded on the basis of sexual orientation. This is just wrong — it undermines rigorous scientific testing and it is morally reprehensible.”

Gillibrand and Menendez also said the any forms of discrimination must be eliminated from the clinical trials.

“Discrimination is wrong in any context, but discrimination in clinical trials is particularly troubling because it limits an entire community’s access to medical care,” Menendez said. “Getting answers on this will help us make sure that these trials are open to every member of our society.”

9 porn agencies to be targeted in labor complaints

LOS ANGELES — An AIDS advocacy group said April 15 it had filed labor complaints against nine porn talent agencies for promoting actors who are willing to have unprotected sex on camera.

The Associated Press reported AIDS Healthcare Foundation President Michael Weinstein said the Los Angeles-area agencies were knowingly exposing the porn actors to sexually transmitted diseases.

The agencies should abide by state labor codes that prevent their licensing if they endanger the health, safety or welfare of their artists, Weinstein said.

“If there were a construction employment agency, they couldn’t say John Doe is available to dangle 100 feet over the ground without a harness,” Weinstein said. “That would be shut down instantaneously.”

The agencies named in the complaint sent last week to the Department of Industrial Relations are A List Talent, ATMLA, Gold Star Modeling, LA Direct Models, Lisa Ann’s Talent Management, Metro Talent Management, SpieglerGirls.com, Type 9 Models Inc. and World Modeling, according to Weinstein.

A porn performer and owner of ATMLA who identified herself as Shy Love said the risks faced by porn actors are similar to those in sports entertainment, where fighters can be exposed to blood, sweat and mucus.

The advocacy group was unfairly targeting the adult industry, Love said.

“We know the risks going in, the same way a fireman or a policeman knows the risks,” Love said. “We are adults, and it is up to us to choose what risks we face. It is not up to the government.”

In February, Los Angeles County public health director Dr. Jonathan Fielding said regulating condom use on porn sets is nearly impossible, citing typically clandestine porn shoots that require little more than a bed and a camera.

The nonprofit foundation has been pushing for mandatory use of condoms in porn films since an HIV outbreak in 2004 spread panic through the industry and briefly shut down production at several studios.

Confinement sought for N.Y. man who spread HIV

ALBANY, N.Y. — A New York man who was convicted of knowingly infecting at least 13 women with the AIDS virus has completed his prison sentence, but he may face civil confinement as a sex offender.

The Associated Press reported Attorney General Andrew Cuomo wants Nushawn Williams held under a law that allows for keeping the most dangerous sex offenders out of communities after they have served their sentences. Williams completed a 12-year sentence April 13.

Williams infected the women in western New York in the late 1990s. He had said at the time that he didn’t believe health officials who told him he was HIV positive.

The process of determining whether Williams’ mental state justifies confinement or intensive supervision could take months. Williams will be held until then. He now goes by the name Shyteek Johnson.

Continue Reading
Advertisement

Commentary

Should we vacation in homophobic countries?

Secret gay bar in St. Petersburg seemed unfathomable

Published

on

(Image by Askonsat Uanthoeng via Pexels)

ST. PETERSBURG, Russia — The tiny rainbow light projecting onto the corner baseboard of the bar and tipsy people constantly belting out Mariah Carey karaoke songs clued me in. There was something unique happening here. It wasn’t until a gentleman with glittered cheeks approached me to say how fabulous my dress was that I suddenly clocked it. I’d unknowingly ended up in a gay bar in the middle of Saint Petersburg, Russia.

A flood of overwhelming joy first took over. Before coming to Russia on vacation, I knew all too well the discrimination and fear LGBTQ Russians lived in. A gay bar in Russia, even a secret one like this, seemed unfathomable, so being where people could unapologetically be out and proud — even if it was only in the compounds of these four walls — was emotionally profound.

But within seconds, dread took over. Were we all safe? If you didn’t know what to look out for, you’d assume this was just like every other neighboring non-gay bar — it wasn’t hidden or anything. I wondered what was stopping a homophobe, if they found out, from vandalizing the bar or doing something much worse.

After all, Russia approved a legislation in 2013 prohibiting the distribution of information about LGBTQ matters and relationships to minors. The legislation, known as the “gay propaganda law,” specifies that any act or event that authorities believe promotes homosexuality to individuals under the age of 18 is a punishable felony. According to a 2018 report by the international rights organization Human Rights Watch, anti-LGBTQ violence in the country spiked after it passed. The bill perpetuates the state’s discriminatory ideology that LGBTQ individuals are a “danger” to traditional Russian family values.

A recent poll indicated that roughly one-fifth of Russians want to “eliminate” gay and lesbian individuals from society. In a poll conducted by the Russian LGBT Network — a Russian queer advocacy group — 56 percent of LGBTQ respondents said they had been subjected to psychological abuse, and disturbing reports of state-sanctioned detention and torture of gay and bisexual men in Chechnya, a semi-autonomous Russian region, have surfaced in recent years.

Considering this, it was no surprise that most of my gay friends refused to come on vacation with me to Russia. In our everyday, gay people don’t march around with a gay Pride flag so homophobic Russians would probably never be able to tell which tourists are gay. However, many LGBTQ people will never travel to Russia or any other homophobic country for one logical reason: Fear.

Unfortunately, many exotic locations abroad are dangerous territory for the LGBTQ community to be in. Physical safety isn’t guaranteed in countries like Nigeria, Iran, Brunei and Saudi Arabia where same-sex relationships are punishable by the death penalty. Not to mention the numerous transgender people who’ve been detained and refused entry to similar countries — even when it’s only been a layover! However, an alternative reason why someone may refuse to vacation in a homophobic country is having a conscience.

When you pay for accommodation, nights out and sightseeing tours, your money doesn’t just reach the hotel staff and waiters pockets — you’re also financially supporting that country’s government. Money talks so not giving homophobic countries tourism puts pressure on them. Ethically, why would anybody ever want to support a country through tourism that treats their LGBTQ community like dirt? Homophobia shouldn’t be shrugged off simply as a local “culture.”

Other LGBTQ people firmly embrace the right to go anywhere they choose, and that choosing to go gives them power. Homophobic countries still have closeted LGBTQ folks living there running underground gay spaces and groups. Is turning our back on the wonderful people and beautiful culture of a new place turning our back on their gay community too? There are countries where gay marriage is legal and trans rights are progressive, but abortion laws remain backwards. Do we boycott these countries too? And, how do we collectively define what a homophobic country is? Is legalizing gay marriage a requisite? Gay marriage is still illegal in Thailand when it is one of the most gay and trans-friendly countries in the world.

Increasingly the line of what is “right” and “wrong” erases all grey areas. Morality and activism — particularly when politics is involved — is never straightforward. The biggest surprise about Russia was how my own stereotypes I’d picked up from the media weren’t always true. Saint Petersburg in Russia is far more liberal and gay-friendly compared to rural Russia but the fact still stands that my bisexual friend and I actively chose to go to a homophobic country for pleasure. In an ideal world, anybody of any sexual orientation or gender identity would be able to vacation wherever they want but that’s sadly not reality. In the meantime, the wanderlust LGBTQ community will go on gay cruises that guarantee safe refuge or put civil rights and ideological differences aside to experience the world’s natural wonders and incredible cultures.

Ash Potter is a writer and radio host.

Continue Reading

Health

FDA approves injectable PrEP to reduce the risk of sexual HIV infection

Manufactured as Apretude, it will be available to at-risk adults & adolescents who weigh at least 77 pounds & have tested negative for HIV

Published

on

FDA headquarters, Silver Spring, MD (Photo Credit: U.S. government/FDA)

SILVER SPRING, Md. – The U.S. Food and Drug Administration announced Monday that the agency had approved the first injectable treatment for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.

Manufactured under the name Apretude, it will be available to at-risk adults and adolescents who weigh at least 77 pounds and have tested negative for HIV immediately beforehand the agency said in a press release.

By granting its approval, the FDA opens up the option for patients to receive the injectable drug instead of a daily HIV prevention oral medication, such as Truvada.

“Today’s approval adds an important tool in the effort to end the HIV epidemic by providing the first option to prevent HIV that does not involve taking a daily pill,” said Debra Birnkrant, M.D., director of the Division of Antivirals in the FDA’s Center for Drug Evaluation and Research. “This injection, given every two months, will be critical to addressing the HIV epidemic in the U.S., including helping high-risk individuals and certain groups where adherence to daily medication has been a major challenge or not a realistic option.”

According to the U.S. Centers for Disease Control and Prevention, notable gains have been made in increasing PrEP use for HIV prevention in the U.S. and preliminary data show that in 2020, about 25% of the 1.2 million people for whom PrEP is recommended were prescribed it, compared to only about 3% in 2015.

However, there remains significant room for improvement. PrEP requires high levels of adherence to be effective and certain high-risk individuals and groups, such as young men who have sex with men, are less likely to adhere to daily medication.

Other interpersonal factors, such as substance use disorders, depression, poverty and efforts to conceal medication also can impact adherence. It is hoped that the availability of a long-acting injectable PrEP option will increase PrEP uptake and adherence in these groups.

The safety and efficacy of Apretude to reduce the risk of acquiring HIV were evaluated in two randomized, double-blind trials that compared Apretude to Truvada, a once daily oral medication for HIV PrEP.

Trial 1 included HIV-uninfected men and transgender women who have sex with men and have high-risk behavior for HIV infection. Trial 2 included uninfected cisgender women at risk of acquiring HIV.

Participants who took Apretude started the trial with cabotegravir (oral, 30 mg tablet) and a placebo daily for up to five weeks, followed by Apretude 600mg injection at months one and two, then every two months thereafter and a daily placebo tablet.

Participants who took Truvada started the trial taking oral Truvada and placebo daily for up to five weeks, followed by oral Truvada daily and placebo intramuscular injection at months one and two and every two months thereafter.

In Trial 2, 3,224 cisgender women received either Apretude or Truvada. The trial measured the rate of HIV infections in participants who took oral cabotegravir and injections of Apretude compared to those who took Truvada orally.

The trial showed participants who took Apretude had 90% less risk of getting infected with HIV when compared to participants who took Truvada.

Apretude includes a boxed warning to not use the drug unless a negative HIV test is confirmed. It must only be prescribed to individuals confirmed to be HIV-negative immediately prior to starting the drug and before each injection to reduce the risk of developing drug resistance.

Drug-resistant HIV variants have been identified in people with undiagnosed HIV when they use Apretude for HIV PrEeP. Individuals who become infected with HIV while receiving Apretude for PrEP must transition to a complete HIV treatment regimen.

The drug labeling also includes warnings and precautions regarding hypersensitivity reactions, hepatotoxicity (liver damage) and depressive disorders.

Continue Reading

Health

FDA slow in responding to calls for end to ban on MSM tissue donors

‘Scientific evidence does not support these restrictions’

Published

on

Tammy Baldwin, gay news, Washington Blade
Sen. Tammy Baldwin (D-Wis.) is a lead signer of the letter to the FDA. (Washington Blade photo by Michael Key)

As of early this week, the U.S. Food and Drug Administration had yet to respond to a Nov. 29 joint letter by 52 members of the U.S. House and U.S. Senate calling on the FDA to end its policy of restricting the donation of human tissues such as corneas, heart valves, skin, and other tissue by men who have sex with men, or MSM.

The letter is addressed to Acting FDA Commissioner Janet Woodcock and Department of Health and Human Services Secretary Xavier Becerra. The FDA is an agency within the HHS.

The letter says the FDA’s restrictions on MSM tissue donation date back to a 1994 U.S. Public Health Service “guidance” related to the possible transmission of HIV, which stated that any man “who has had sex with another man in the preceding five years” should be disqualified from tissue donation.

“We also call your attention to the broad consensus within the medical community indicating that the current scientific evidence does not support these restrictions,” the letter states. “We have welcomed the FDA’s recent steps in the right direction to address its discriminatory MSM blood donation policies and urge you to take similar actions to revise the agency’s tissue donation criteria to align with current science so as not to unfairly stigmatize gay and bisexual men.”

The letter adds, “In fact, a recent study in the medical journal JAMA Ophthalmology estimated that between 1,558 and 3,217 corneal donations are turned away annually from otherwise eligible donors who are disqualified because of their sexual orientation, an unacceptable figure given widespread shortages of transplantable corneas.”

The letter continues, saying, “FDA policy should be derived from the best available science, not historic bias and prejudice. As with blood donation, we believe that any deferral policies should be based on individualized risk assessment rather than a categorical, time-based deferral that perpetuates stigma.”

U.S. Sen. Tammy Baldwin (D-Wisc.), the nation’s only out lesbian U.S. senator, and U.S. Rep. Joe Neguse (D-Colo.) are the two lead signers of the letter. All 52 signers of the letter are Democrats.

Among the others who signed their names to the FDA letter are four of the nine openly gay or lesbian members of the U.S. House. They include Reps. David Cicilline (D-R.I.), Richie Torres (D-N.Y.), Mondaire Jones (D-N.Y.), and Mark Takano (D-Calif.). 

Also signing the letter are D.C. Congressional Del. Eleanor Holmes Norton (D-D.C.), and Rep. Jamie Raskin (D-Md.). 

In response to a Dec. 21 email inquiry from the Washington Blade, FDA Press Officer Abigail Capobianco sent the Blade a one-sentence statement saying, “The FDA will respond to the letter directly.”

The statement didn’t say to whom the FDA would respond or when it would issue its response.

https://neguse.house.gov/imo/media/doc/FINAL%20-%20Letter%20to%20FDA%20and%20HHS%20on%20Corneal%20Tissue%20Donations.pdf

Continue Reading
Advertisement
Advertisement

Follow Us @washblade

Sign Up for Blade eBlasts

Popular